Eton Pharmaceuticals. Eton Pharmaceuticals expands rare disease portfolio through acquisition of U.S. commercialization rights to HEMANGEOL® (propranolol hydrochloride) oral solution. Eton ...

In today's Pharma Pulse, the FDA expands the pediatric indication for Juxtapid to treat rare homozygous familial hypercholesterolemia, while Novo Nordisk announces a major €432 million investment in ...

The FDA has transitioned to a "new era" of proactive enforcement, issuing warning letters to telehealth and pharmaceutical companies to eliminate misleading promotional claims and ensure a fair ...

Global life sciences supply chain conference LogiPharma has announced a brand-new series of interactive formats for 2026 under the leadership of incoming event director, Ben Sharples.

SpotSee and Controlant announced a collaboration to enhance pharmaceutical supply chain visibility using integrated ...

Thermal testing can make or break cold chain performance. Join this webinar to learn proven best practices that help eliminate blind spots, validate designs, and protect temperature-sensitive ...

The FDA granted accelerated approval to Boehringer Ingelheim’s Hernexeos for first-line HER2-mutant NSCLC following a 44-day ...

In today’s Pharma Pulse, the FDA grants priority review to a therapy for polycythemia vera, while Novo Nordisk receives expanded pediatric approval for its once-weekly growth hormone.

In today's Pharma Pulse, the FDA expands the pediatric indication for Juxtapid to treat rare homozygous familial hypercholesterolemia, while Novo Nordisk announces a major €432 million investment in ...

Medicare negotiation applies first to Part D retail drugs and later to Part B physician-administered agents, with negotiated ...

A conversation with Kenco’s Tim McClatchy explores how pharmaceutical logistics providers are strengthening cybersecurity ...

In today’s Pharma Pulse, the FDA grants a lightning-fast approval for Boehringer’s lung cancer therapy under its new priority program, while CMS Administrator Mehmet Oz launches a sweeping offensive ...